Ligand Pharmaceuticals, Inc. (LGND)
280.18
-6.11
(-2.13%)
USD |
NASDAQ |
Aug 24, 16:00
280.04
-0.14
(-0.05%)
After-Hours: 20:00
Ligand Pharmaceuticals Enterprise Value : 5.355B for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 5.355B |
| August 21, 2026 | 5.477B |
| August 20, 2026 | 5.499B |
| August 19, 2026 | 5.565B |
| August 18, 2026 | 5.502B |
| August 17, 2026 | 5.586B |
| August 14, 2026 | 5.642B |
| August 13, 2026 | 5.527B |
| August 12, 2026 | 5.616B |
| August 11, 2026 | 5.526B |
| August 10, 2026 | 5.664B |
| August 07, 2026 | 5.613B |
| August 06, 2026 | 5.752B |
| August 05, 2026 | 5.801B |
| August 04, 2026 | 5.765B |
| August 03, 2026 | 5.591B |
| July 31, 2026 | 5.501B |
| July 30, 2026 | 5.676B |
| July 29, 2026 | 5.511B |
| July 28, 2026 | 5.676B |
| July 27, 2026 | 5.700B |
| July 24, 2026 | 5.760B |
| July 23, 2026 | 5.793B |
| July 22, 2026 | 5.835B |
| July 21, 2026 | 5.859B |
| Date | Value |
|---|---|
| July 20, 2026 | 5.630B |
| July 17, 2026 | 5.817B |
| July 16, 2026 | 5.679B |
| July 15, 2026 | 5.675B |
| July 14, 2026 | 5.769B |
| July 13, 2026 | 5.934B |
| July 10, 2026 | 6.073B |
| July 09, 2026 | 6.200B |
| July 08, 2026 | 6.046B |
| July 07, 2026 | 6.137B |
| July 06, 2026 | 6.156B |
| July 02, 2026 | 6.139B |
| July 01, 2026 | 5.989B |
| June 30, 2026 | 6.070B |
| June 29, 2026 | 5.962B |
| June 26, 2026 | 5.753B |
| June 25, 2026 | 5.600B |
| June 24, 2026 | 5.379B |
| June 23, 2026 | 5.269B |
| June 22, 2026 | 4.924B |
| June 18, 2026 | 5.178B |
| June 17, 2026 | 4.943B |
| June 16, 2026 | 4.785B |
| June 15, 2026 | 4.745B |
| June 12, 2026 | 4.791B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Johnson & Johnson | 685.82B |
| Eli Lilly & Co. | 1.220T |
| Merck & Co., Inc. | 418.70B |
| Zevra Therapeutics, Inc. | 471.26M |
| Liquidia Corp. | 6.160B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 48.51M |
| Revenue (Quarterly) | 63.69M |
| Total Expenses (Quarterly) | 15.18M |
| EPS Diluted (Quarterly) | 2.221 |
| Gross Profit Margin (Quarterly) | 82.24% |
| Profit Margin (Quarterly) | 76.16% |
| Earnings Yield | 3.34% |
| Operating Earnings Yield | 1.71% |
| Normalized Earnings Yield | 2.512 |